Replies to post #149157 on Elite Pharmaceuticals Inc (ELTP)

[sharpei]

Wow! Fantastic reporting, WeeZuhl. As someone mentioned yesterday this board is blessed with several highly qualified persons in the field of medicine and biotechnology who give of their time and expertise to educate 'us huddled masses' in the science of a special line of therapeutics to which we have all so willingly committed ourselves and precious resources. Deepest gratitude to you and others.

[Gman24]

Great post.. And welcome to the board..!!

[tempaussie]

Up early this morning and this was the first post I read. Wonderful explanation to those of us who awoke in an Holiday Inn Express.

Your story of Contrave's adventures are a wet mop across the face to those few posters here who are constantly clamoring for news every day. We are not looking at a one hit wonder and a good foundation will pay off beyond anything we can conjure up in our minds.

[no2koolaid]

Outstanding insights from your medical perspective and, for a medical doctor, keen observation on the value of effective management. Some have decried the actions of Elite, its management, and, of course, its CEO. While no one is perfect and there have been some things that have not happened as stated or planned, to this point they have happened. This is the hallmark of an effective management team. They grasp the realities and understand that success is not a straight line, but an adaptive reaction to environmental factors they cannot control. However, it is the effective reaction that we have seen from Nasrat and team that we should trust. In truth, with some understanding of how organizations work, it is what we cannot see but know must be occurring that is truly exciting for shareholders.

Also, your observation about Orexigen Therapeutics is spot on. Shareholders of various small pharma firms have seen their CEOs jump to conclusions and interviews on MSNBC & Fox Business to hawk their brilliance and that of their drugs (e.g.; Mannkind, Ariad Pharma, Northwest Bio), only to see a short run up followed by a notable beat down. I trust Nasrat pays attention to such things and, while he can be the cheerleader for investors (which is part of the CEOs role), he will take a measured approach with the FDA. So, I can wait for the right news, not the most convenient.

[lasers]

WeeZuhl The short answer is no because Naltrexone in Contrave is the API Naltrexone and not the ANDA or the NDA.

Will ELTP Generic Naltrexone Generate Bariatric Revenue?

Same answer as $ELTP's ADTs will not be helped by $ELTP's approved ANDA with all of its excipients whereas the Naltrexone in $ELTP's ADTs is the pure API Naltrexone. The same case as for Orexigen/Takeda's Contrave.

Hopefully that helps.

I want to thank you for all of your excellent DD and taking the time to add your Doctor MD experience to this MB. It is very much appreciated.

[julesnemo3]

Excellent post WeeZuhl. Glad to see new postings from new investors who have found ELTP. Positive, intelligent and informative postings from fellow ELTP shareholders are always welcome. Many here know what a gem this company is on the OTC. Good fortune to you and all longs.

[dr_lowenstein]

not likely. I always check the literature. for example:

Given these observations, naltrexone was seen as a potential obesity treatment and several studies have been performed and published since the early 1980s. However, the results of these studies59–64 were disappointing, because naltrexone monotherapy was associated with minimal or no weight loss.29 The limited efficacy of a single obesity agent such as naltrexone might be explained because of the various different mechanisms regulating caloric intake and body weight.65 Therefore, a combination of drugs would be a better option.

Like that?? Minimal or no weight loss. hmmmmmmmmmmmmmmmm